Key result
Inhibitors of the Kv1.3 potassium channel in immune cells provide a mechanistic rationale for use as a potential therapy for multiple sclerosis and other autoimmune disorders.
Why the study?
Do inhibitors of the Kv1.3 K+ channel have therapeutic potential for multiple sclerosis and other autoimmune disorders?
Population
Patients with multiple sclerosis and other autoimmune disorders
Design
Review
Authors
Loading...
May inform novel MS immunomodulation; leaves open clinical efficacy and safety in trials.
Do inhibitors of the Kv1.3 K+ channel have therapeutic potential for multiple sclerosis and other autoimmune disorders?
This review outlines the rationale for targeting Kv1.3 K+ channels in immune cells to treat multiple sclerosis and autoimmune diseases.
Beeton et al. (2005) studied this question. Inhibitors of the Kv1.3 potassium channel in immune cells provide a mechanistic rationale for use as a potential therapy for multiple sclerosis and other autoimmune disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: